Fesariustherapeutics Inc.
New York, NY
- UEI
- YTNJCJM8KS58
- CAGE
- 7EV34
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 619 W 54th St Fl 9, New York, NY 10019, USA
- Website
- fesariustherapeutics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Fesariustherapeutics Inc.
Fesariustherapeutics Inc. is a corporate entity located in New York City that specializes in advanced biomedical research and product development, particularly in the field of wound treatment and dermal regeneration technologies. Registered in SAM.gov since July 2015, the company operates as a for-profit organization and manufacturer of medical goods, with a focused research portfolio centered on innovative dermal regeneration solutions. The company's primary technological development is Dermisphere, an antimicrobial dermal regeneration template designed to address complex wound healing challenges across multiple medical contexts.
The company has secured multiple federal grant awards from prominent medical research agencies, specifically the National Institute of General Medical Sciences (NIGMS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. These project grants, totaling approximately $699,237, have supported the development of the Dermisphere product for various medical applications, including wound treatment in challenging environments such as burn wounds, traumatic injuries, post-oncologic reconstructive surgery, and infection-related skin loss. The grants focus on advancing the Dermisphere technology through preclinical development, large animal studies, biocompatibility testing, and user validation, with the ultimate goal of achieving FDA 510(k) approval and initiating human clinical trials. The research aims to create a dermal regeneration scaffold that promotes rapid cellular infiltration, angiogenesis, and accelerated wound healing, potentially offering significant improvements over existing wound treatment technologies.
SBA capabilities narrative
Fesarius manufactures DermiSphere(tm), a dermal regeneration scaffold for use in wound care including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds (donor sites/grafts, post-Mohs surgery, post-oncologic, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds.
Quick answers
What is Fesariustherapeutics Inc.'s UEI?
Fesariustherapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is YTNJCJM8KS58.
What is Fesariustherapeutics Inc.'s CAGE code?
Fesariustherapeutics Inc.'s CAGE code is 7EV34.
What is Fesariustherapeutics Inc.'s primary NAICS code?
Fesariustherapeutics Inc.'s primary NAICS code is 325414 (Biological Product (except Diagnostic) Manufacturing).
Where is Fesariustherapeutics Inc. located?
Fesariustherapeutics Inc.'s physical address in SAM.gov is 619 W 54th St Fl 9, New York, NY 10019, USA.
Is Fesariustherapeutics Inc. registered in SAM.gov?
Yes. Fesariustherapeutics Inc.'s SAM.gov registration is active through March 19, 2027.
What is Fesariustherapeutics Inc.'s most recent federal award?
Fesariustherapeutics Inc.'s most recent federal grant award is An antimicrobial dermal regeneration template for application in challenging wound environments - project… (R43GM161193), from National Institute of General Medical Sciences, on September 1, 2025.
On GovTribe
See Fesariustherapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors